Abstract. Aims. A missense mutation in the low density lipoprotein receptor-related protein 6 gene (LRP6) was recently shown to be responsible for a disorder characterized by early-onset coronary artery disease as well as diabetes mellitus (DM), hyperlipidemia, hypertension, and osteoporosis. Mice deficient in LRP5, a closely related paralog of LRP6, manifest a marked impairment in glucose tolerance. The aim of the present study was to examine whether common variants of LRP5 and LRP6 are associated with Type 2 DM or dyslipidemia in Japanese individuals. Methods. Thirteen single nucleotide polymorphisms (SNPs) of LRP6 and nine SNPs of LRP5 were genotyped in a total of 608 Type 2 DM patients and 366 nondiabetic control subjects (initial study). An association analysis was then performed for each SNP and for haplotypes. For some of the SNPs, we provided another sample panel of 576 cases and 576 controls for the replication study. The relation to clinical characteristics was also examined in diabetic subjects. Results. In the initial study, three SNPs of LRP6 were found to be associated with susceptibility to Type 2 DM. However, this association was not detected in the replication panel. None of SNPs in LRP5 were associated with Type 2 DM in the initial panel. Neither LRP6 nor LRP5 was associated with body mass index, HOMA-β, HOMA-IR or serum lipid concentrations. Conclusions. We found no evidence for a substantial effect of LRP5 or LRP6 SNPs on susceptibility to type 2 diabetes or clinical characteristics of diabetic subjects in Japanese population.
THE common form of Type 2 diabetes mellitus (DM) results from a complex interaction between genetic background and the environment. Identification of susceptibility genes for Type 2 DM has proven difficult because of the multifactorial nature of the disease. Genes responsible for monogenic disorders are potential contributors to similar conditions with a multifactorial etiology. A missense mutation (R611C) in the low density lipoprotein (LDL) receptor-related protein 6 gene (LRP6) was recently shown to be causally linked to a dominant form of early-onset coronary artery disease in an Iranian family. This mutation was also linked to DM, hyperlipidemia, hypertension, and osteoporosis in the same family [1] . Mice deficient in LRP5, a closely related paralog of LRP6, manifest a marked impairment in glucose tolerance [2] . LRP5 and LRP6 are members of the LDL receptor family [3] and function as co-receptors for Wnt ligands, playing an important role in Wnt signaling [4] . The transcription factor 7-like 2 gene (TCF7L2) shows a reproducible association with Type 2 DM [5] in multiple populations, and the encoded protein also plays a role in Wnt signaling [6] .
These various observations suggest that LRP5 and LRP6 are potential susceptibility genes for Type 2 DM. We therefore examined whether common variants of LRP5 and LRP6 might be associated with Type 2 DM or dyslipidemia in Japanese individuals.
Subjects and Methods

Subjects
A total of 608 unrelated individuals with Type 2 DM and 366 unrelated nondiabetic control subjects were enrolled for the initial study. We provided another sample panel of 576 cases and 576 controls for the replication study (replication panel). In the initial panel, the mean ± SD of age, body mass index (BMI), and HbA 1c were 61.3 ± 9.9 years, 23.8 ± 3.4 kg/m 2 , and 7.9 ± 1.8%, respectively, for the diabetic subjects and 75.4 ± 8.1 years, 21.5 ± 3.6 kg/m 2 , and 5.0 ± 0.4%, respectively, for the control subjects. In the replication panel, those for the cases were 60.2 ± 11.5 years, 23.9 ± 4.2 kg/m 2 , and 7.8 ± 3.5%, respectively and, for the controls, 67.3 ± 6.5 years, 23.0 ± 2.9 kg/m 2 , and 5.0 ± 0.4%, respectively. The diagnosis of Type 2 DM was based on the criteria of the American Diabetes Association (1997). The nondiabetic subjects were selected according to the following criteria: age of >60 years (only for the initial panel), no past history of glucose intolerance, HbA 1c content of ≤5.7%, and no family history of DM. The study was performed with written informed consent from all subjects and was approved by the Ethics Committee of Kobe University Graduate School of Medicine or of Gifu University School of Medicine.
Clinical assessment
The BMI of each individual was directly measured at the time of collection of blood samples. [8] . Among the 608 diabetic subjects of the initial panel, the 467 individuals who had not been treated with insulin were evaluated for HOMA-IR, HOMA-β, and FPG, whereas the 422 individuals who had not taken lipid-lowering drugs were evaluated for lipid parameters.
DNA analysis
We selected 13 single nucleotide polymorphisms (SNPs) of LRP6 (Fig. 1A) and nine SNPs of LRP5 ( Fig. 2A ) from the HapMap database (http://www. hapmap.org) according to the inclusion criteria as follows: minor allele frequencies >0.10 (except a nonsynonymous polymorphism, rs2302685 in LRP6) and linkage disequilibrium (LD) by r 2 <0.8 in the Japanese data (JPT). Genomic DNA was extracted from blood with the use of a QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA), and genotypes for the SNPs were determined with the TaqMan procedure (Applied Biosystems, Foster City, CA). The polymerase chain reaction was performed with ABsolute QPCR ROX Mixes (ABgene, Epsom, UK) and an ABI PRISM 7700 Sequence Detector System (Applied Biosystems); the amplification protocol included incubation at 95°C for 15 min followed by 40 cycles of 92°C for 15 s and 60°C for 1 min. Sequencing of exon 9 of LRP6 was performed with the use of a Big Dye Terminator Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems) and an automated DNA capillary sequencer (model 3100, Applied Biosystems).
Statistical analysis
We assessed association and Hardy-Weinberg equilibrium with the chi-square test. Linkage disequilibrium and haplotype analyses including permutation tests were performed with SNPAlyze version 5.1 pro software (Dynacom, Mobara, Japan). Haplotype estimation was performed by the expectation-maximization algorithm [9] . If we assume a minor allele frequency of 0.24, odds ratio of 1.3, and type I error probability (α) of 0.05, the power of our initial sample (608 cases and 366 controls) computed by the PS program [10] is 0.82. In case of combined sample (1184 cases and 942 controls), the power is 0.98. Averaged data are pre-sented as means ± SD, and differences between groups were analyzed by ANOVA; if necessary, data were log transformed. Statistical analysis was performed with StatView software version 5.0-J (SAS Institute, Cary, NC). A P value of <0.05 was considered statistically significant.
Results
LRP6
For analysis of LD in the LRP6 genomic region, we genotyped 13 SNPs in 92 nondiabetic control subjects.
The D' and r 2 values for the 92 control subjects are shown in Fig. 1B . Two SNPs (SNP6-3, SNP6-8) were excluded from further genotyping because of their absolute LD. The remaining 11 SNPs, including a nonsynonymous polymorphism (I1062V, SNP6-11), were genotyped in all 608 Type 2 DM subjects and 366 control subjects. All SNPs with the exception of SNP6-13 were in Hardy-Weinberg equilibrium (P>0.01). Association results for the 11 genotyped SNPs are shown in Table 1 . We found associations between three SNPs (SNP6-1, SNP6-2, SNP6-7) and susceptibility to Type 2 DM. SNP6-7 showed the strongest association (odds ratio = 0.74, 95% confidence interval = 0.59 to 0.93, P = 0.008). SNP6-2 and SNP6-7 were in strong LD with each other (r 2 = 0.94) in the 92 control subjects tested for LD. We also sequenced exon 9 of LRP6, which contains the previously identified missense mutation R611C [1] . No polymorphism was detected in the 24 diabetic and 24 control subjects subjected to such direct sequencing. An LD block spanning SNP6-2 to SNP6-7 (Fig. 1B ) encompassed a region containing exons 2 and 3 of LRP6 but did not include exon 9. Although we performed haplotype analysis with SNP6-7 and the other SNPs, we did not detect an association with Type 2 DM more significant than that of SNP6-7. A haplotype comprising SNP6-5 = A and SNP6-7 = G showed an association with Type 2 DM similar to that of SNP6-7 alone (estimated haplotype frequencies of 0.19 and 0.24 in diabetic and control subjects, respectively; permutation P value computed by 10,000 permutations = 0.006).
When we consider multiple testing for the number of SNPs (P<0.05/9 SNPs; where four of 13 SNPs are not counted because of strong LD of r 2 >0.8), the LD block including SNP6-7 is the most likely to be associated with the susceptibility to Type 2 DM. Therefore, we did not include SNP6-1 for further analysis (P value of SNP6-1 = 0.042). In order to examine a replication for the association of the SNPs or the LD block, SNP6-5 and SNP6-7 were genotyped in an independent sample panel (replication panel). However, none of these two SNPs or haplotypes were associated with Type 2 DM in the replication panel (Table 2 for SNPs, data not shown for haplotypes). No association was apparent when we combined the initial panel and the replication panel (Table 2 ).
Finally, we examined the relation of SNP6-7 to clinical characteristics in the diabetic subjects of the initial panel. However, no apparent association was found with BMI, HOMA-IR, HOMA-β, or serum lipid parameters (Table 3) . 
LRP5
Nine SNPs including a non-synonymous SNP (A1330V, SNP5-8) were genotyped in 92 control subjects. The D' and r 2 values for these subjects are shown in Fig. 2B . Then all polymorphisms were genotyped in the initial panel of 608 Type 2 DM subjects and 366 control subjects. They were in HardyWeinberg equilibrium (P>0.01).
The results of association tests for susceptibility to Type 2 DM are shown in Table 4 . No association between SNPs of LRP5 and Type 2 DM was apparent in this panel. Next, we assessed the relations between all SNPs and clinical characteristics, BMI, HOMA-IR, HOMA-β, or serum lipid parameters in the diabetic subjects. However, no association was detected (data not shown).
Discussion
We found no evidence for a substantial effect of LRP5 or LRP6 SNPs on susceptibility to type 2 DM in Japanese population. The association of rs2417086 (SNP6-7) or haplotype analysis in LRP6 observed in the initial panel could be false positive due to the small sample number. A previous study showed that a mutation in LRP6 was genetically linked with a familial disorder characterized by early-onset coronary artery disease as well as hyperlipidemia, hypertension, DM, and osteoporosis [1] . Genes that cause rare monogenic disorders might also confer susceptibility to similar conditions with a multifactorial etiology, although we failed to detect such a case. For example, genes responsible for maturity-onset diabetes of the young, an autosomal dominant monogenic form of DM, have also been associated with Type 2 DM [11] [12] [13] [14] . Data are means ± SD. P values were calculated by ANOVA. *These parameters were log transformed before analysis. LRP5 and LRP6 are co-receptors for Wnt ligands [4, 15] . Wnt signaling is necessary for embryogenesis but also plays important roles in postnatal development and tissue homeostasis. Mouse embryos homozygous for an insertion mutation in Lrp6 exhibit a variety of severe developmental abnormalities, including midbrain defects, truncation of the skeleton, and limb anomalies [4] . Lrp6 mutations cause early-onset osteoporosis in mice [16] . Lrp5 -/-mice exhibit low bone density and frequent bone fractures. In human, mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG) [17, 18] . Recently, some reports showed that polymorphisms of LRP5 were associated with bone mineral density [19] [20] [21] . Meanwhile, LRP5 plays an important role in glucose and lipid metabolism, with Lrp5 knockout mice showing a marked impairment in glucose tolerance as a result of a reduced level of glucose-induced insulin secretion. Maintenance of these knockout mice on a high-fat diet also increases the plasma concentration of cholesterol to levels greater than those apparent in similarly fed normal mice [2] . We assessed whether polymorphisms of LRP5 or LRP6 were associated with HOMA-IR, HOMA-β, or lipid parameters in patients with Type 2 DM. However, no such association was detected. We did not evaluate whether the polymorphisms were associated with osteoporosis or cardiovascular disease because information was not available for these disorders. Recently, Guo et al. showed that a haplotype including rs4988300 (SNP5-2) in LRP5 was associated with BMI in Caucasian diabetic subjects [22] . Although we investigated the association between BMI and this polymorphism or haplotypes comprising SNP5-1 to SNP5-3, there was no association (data not shown).
To date, TCF7L2 (also known as TCF4) has been the gene most reproducibly associated with Type 2 DM [5] . TCF7L2 is a transcription factor that partners with β-catenin in the canonical Wnt signaling pathway [6] . Wnt signaling and β-catenin are necessary for the proliferation of pancreas including β cells in mice [23] [24] [25] . Elucidation of the mechanisms by which this signaling pathway contributes to regulation of glucose metabolism may provide insight into the pathogenesis of Type 2 DM.
In conclusion, our results failed to reveal an association between Type 2 DM and SNPs or haplotypes of LRP5 and LRP6. Furthermore, we found no association between these genes and any clinical characteristics such as serum LDL-cholesterol in the subjects with Type 2 DM. Similar studies are needed to clarify whether variants of LRP5 and LRP6 may be associated with coronary artery disease, hyperlipidemia, hypertension as well as Type 2 DM.
